The combination of biologic drugs and GLP-1 agonists, offers a new therapeutic dimension for the treatment of psoriasis, in which both overweight and the associated dysmetabolism are addressed at the same time as the skin and/or joint manifestations of psoriasis
All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice
A $15,000 annual GLP-1 spend that delivers single-digit weight loss, no meaningful metabolic improvements and a high discontinuation rate is not a solid investment
Research has examined its role in: GH secretion stimulation via selective GHS-R1a agonism IGF-1 axis modulation and downstream anabolic signalling research Longitudinal bone growth and bone mineral content investigations Body composition and lean tissue research in pre-clinical models Comparative GHRP selectivity and receptor-binding studies Postoperative gastrointestinal motility research via ghrelin receptor pathways Synergistic GH axis research when combined with GHRH analogues such as CJC-1295 Ipamorelin and Longitudinal Bone Growth Research In adult female rats administered Ipamorelin subcutaneously three times daily for 15 days, a dose-dependent increase in longitudinal bone growth rate was observed rising from 42 m/day in the vehicle group to 52 m/day at the highest dose confirming GH-mediated effects on skeletal tissue in pre-clinical models
About a third exceeded 20%
An updated knowledge of Black seed ( Nigella sativa Linn.): Review of phytochemical constituents and pharmacological properties
